Aurinia Pharmaceuticals (AUPH) Assets (2016 - 2026)
Aurinia Pharmaceuticals' (AUPH) quarterly Assets came in at $724.0 million in Q1 2026, up 43.41% YoY from $504.8 million in Q1 2025, and down 3.67% on a QoQ basis from $751.6 million in Q4 2025.
Aurinia Pharmaceuticals (AUPH) Assets (2016 - 2026) Analysis & Trends
Aurinia Pharmaceuticals (AUPH) has 11 years of Assets data on file, last reported at $724.0 million in Q1 2026.
- Quarterly Assets rose 43.41% year-over-year to $724.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $724.0 million (up 43.41% YoY) and the FY2025 annual result came in at $751.6 million, up 36.49% from the prior year.
- Assets fell to $724.0 million in Q1 2026, from $751.6 million in the prior quarter.
- In the past five years, Assets ranged from a high of $751.6 million in Q4 2025 to a low of $451.8 million in Q1 2023.
- A 5-year average of $541.3 million and a median of $523.5 million in 2024 frame the typical range for Assets.
- Annual changes were most pronounced in 2022 — Assets dropped 13.34% — and 2026, when it soared 43.41%.
- Tracing AUPH's Assets over 5 years: stood at $470.9 million in 2022, then climbed by 16.4% to $548.1 million in 2023, then advanced by 0.47% to $550.6 million in 2024, then jumped by 36.49% to $751.6 million in 2025, then retreated by 3.67% to $724.0 million in 2026.
- The last three Assets figures came in at $724.0 million (Q1 2026), $751.6 million (Q4 2025), and $527.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Aurinia Pharmaceuticals | 2.06 Bn | 1.61 Bn | 76.67 Mn | 792.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 792.26 Mn |
| Mar 31, 2026 | 724.00 Mn |
| Dec 31, 2025 | 751.59 Mn |
| Sep 30, 2025 | 527.53 Mn |
| Jun 30, 2025 | 502.56 Mn |
| Mar 31, 2025 | 504.85 Mn |
| Dec 31, 2024 | 550.65 Mn |
| Sep 30, 2024 | 549.36 Mn |
| Jun 30, 2024 | 523.53 Mn |
| Mar 31, 2024 | 516.63 Mn |
| Dec 31, 2023 | 548.06 Mn |
| Sep 30, 2023 | 555.01 Mn |
| Jun 30, 2023 | 548.90 Mn |
| Mar 31, 2023 | 451.76 Mn |
| Dec 31, 2022 | 470.86 Mn |
| Sep 30, 2022 | 488.29 Mn |
| Jun 30, 2022 | 482.15 Mn |
| Mar 31, 2022 | 506.90 Mn |
| Dec 31, 2021 | 543.37 Mn |
| Sep 30, 2021 | 360.07 Mn |